Urology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

This Phase 2 trial (NCT07741448) is exploring a new combination treatment for patients with HER2-positive upper tract urothelial carcinoma (UTUC). By using gemcitabine along with trastuzumab rezetecan before surgery, the study aims to increase the chance of completely eliminating cancer cells prior to surgery. For patients, this could mean a more effective treatment option that improves surgical outcomes and long-term control of their cancer. The trial is currently recruiting 54 patients in China.

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

This study (NCT06262516) is investigating whether adding lymph node removal to the standard surgery for upper tract urothelial carcinoma helps reduce cancer recurrence and improve survival rates. Patients undergoing nephroureterectomy surgery might benefit if lymph node dissection proves to provide better disease control. The trial is actively recruiting adults in the United States who are eligible for this surgery, aiming to provide clearer guidance on the best surgical approach.

Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

In this Phase 2 trial (NCT04047693), researchers tested a chemotherapy regimen called dose dense MVAC before surgery in patients with muscle invasive bladder cancer and locally advanced urothelial carcinoma. Although this study was conducted in South Korea, it has been terminated and currently does not have posted results. The treatment was designed to improve safety and effectiveness before surgery, which could benefit patients if future research confirms these goals.

Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

This study (NCT07793240) is looking at how a blood test that detects tumor DNA could help manage high grade upper tract urothelial cancer around the time of surgery. By tracking circulating tumor DNA, doctors may be able to better understand how the cancer is responding to treatment and tailor therapies accordingly. This trial is recruiting 20 patients in the United States and could lead to less invasive ways to monitor the disease.

AI-Guided TURBT for Bladder Cancer

This upcoming study (NCT07727343) will test an artificial intelligence navigation system designed to assist surgeons during bladder tumor removal surgery. The goal is to improve the accuracy of tumor identification and help patients remain cancer-free after surgery. Although the trial is not yet recruiting, it plans to enroll about 170 patients at a single center, potentially offering new technology to enhance surgical outcomes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.